Skip to content

Fenebrutinib in Relapsing MS: FENhance Trial Results Explained

April 22, 2026 · 26 min

Show notes

New Phase 3 data presented at the AAN conference 2026 provide compelling evidence that fenebrutinib may represent a high-efficacy oral treatment option for people living with relapsing multiple sclerosis.

In this exclusive episode, leading experts Prof. Ludwig Kappos from University of Basel and Dr. Jiwon Oh from Barlo MS Centre join host Brett Drummond to unpack the full FENhance 1 & 2 trial results.

Together, they explore:

  • How fenebrutinib performed against teriflunomide in relapsing MS
  • Why BTK inhibition continues to generate strong interest across the MS treatment landscape
  • What the results reveal about relapse reduction, MRI outcomes, and disability progression
  • What the safety profile of fenebrutinib looked like in this cohort of patients

Listen for a deep dive into the science, clinical context, and future implications for MS care.

-----------------------------

This ECTRIMS podcast episode is supported by an educational grant from Alexion, AstraZeneca Rare Diseases. Bristol Myers Squibb, Novartis, Roche, Sanofi, and UCB. Educational grant providers have no input into the podcast series content.

All episodes of The ECTRIMS Podcast

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.